ES2605254T3 - Método de diagnóstico o de pronóstico de cáncer epitelial de ovario - Google Patents

Método de diagnóstico o de pronóstico de cáncer epitelial de ovario Download PDF

Info

Publication number
ES2605254T3
ES2605254T3 ES09785026.7T ES09785026T ES2605254T3 ES 2605254 T3 ES2605254 T3 ES 2605254T3 ES 09785026 T ES09785026 T ES 09785026T ES 2605254 T3 ES2605254 T3 ES 2605254T3
Authority
ES
Spain
Prior art keywords
cev
sox11
cancer
prognosis
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09785026.7T
Other languages
English (en)
Spanish (es)
Inventor
Carl Arne Krister Borrebaeck
Sara Charlotte Andersson Ek
Donal John Brennan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovia AB
Original Assignee
Immunovia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia AB filed Critical Immunovia AB
Application granted granted Critical
Publication of ES2605254T3 publication Critical patent/ES2605254T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/57545—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES09785026.7T 2008-09-01 2009-09-01 Método de diagnóstico o de pronóstico de cáncer epitelial de ovario Active ES2605254T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0815846.1A GB0815846D0 (en) 2008-09-01 2008-09-01 diagnosis, prognosis and imaging of disease
GB0815846 2008-09-01
PCT/GB2009/002098 WO2010023458A1 (en) 2008-09-01 2009-09-01 Method of diagnosing or prognosing epithelial ovarian cancer

Publications (1)

Publication Number Publication Date
ES2605254T3 true ES2605254T3 (es) 2017-03-13

Family

ID=39866018

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09785026.7T Active ES2605254T3 (es) 2008-09-01 2009-09-01 Método de diagnóstico o de pronóstico de cáncer epitelial de ovario

Country Status (7)

Country Link
US (4) US20110217238A1 (enExample)
EP (1) EP2329042B1 (enExample)
JP (1) JP2012501318A (enExample)
CN (1) CN102186994A (enExample)
ES (1) ES2605254T3 (enExample)
GB (1) GB0815846D0 (enExample)
WO (1) WO2010023458A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101680896A (zh) 2007-03-27 2010-03-24 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
GB0910620D0 (en) * 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
US9230153B2 (en) 2011-07-20 2016-01-05 Mikroscan Technologies, Inc. Networkbased pathology system with desktop slide scanner
WO2013176958A1 (en) * 2012-05-21 2013-11-28 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
EP3069183A4 (en) 2013-11-15 2017-06-28 Mikroscan Technologies Inc. Geological scanner
WO2016069794A1 (en) 2014-10-28 2016-05-06 Mikroscan Technologies, Inc. Microdissection viewing system
US20170097355A1 (en) * 2015-10-06 2017-04-06 University Of Washington Biomarkers and methods to distinguish ovarian cancer from benign tumors
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy
EP1644522A2 (en) * 2003-07-02 2006-04-12 Novartis AG Genes regulated in ovarian cancer as prognostic and therapeutic targets
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer

Also Published As

Publication number Publication date
US20220390452A1 (en) 2022-12-08
EP2329042A1 (en) 2011-06-08
EP2329042B1 (en) 2016-10-26
JP2012501318A (ja) 2012-01-19
GB0815846D0 (en) 2008-10-08
US20110217238A1 (en) 2011-09-08
US20160047815A1 (en) 2016-02-18
WO2010023458A1 (en) 2010-03-04
CN102186994A (zh) 2011-09-14
US20190018016A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
ES2605254T3 (es) Método de diagnóstico o de pronóstico de cáncer epitelial de ovario
JP5219029B2 (ja) 食道ガン及び食道ガン転移診断のための組成物及び方法
ES2424329T3 (es) Diagnóstico molecular y clasificación de melanoma maligno
Yanamoto et al. Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: effect of neoadjuvant chemotherapy on local recurrence
ES2355388T3 (es) Métodos para la detección precoz de cáncer.
ES2367412T3 (es) Uso de la proteína satb2 como marcador para distinguir el cáncer colorrectal de otros cánceres.
EP1599603A1 (en) Methods of diagnosis and prognosis of pancreatic cancer
Konishi et al. Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma
Lu et al. Expression of claudin-11,-23 in different gastric tissues and its relationship with the risk and prognosis of gastric cancer
Zhao et al. Tumor‐derived proliferative CTCs and CTC clusters predict aggressiveness and early recurrence in hepatocellular carcinoma patients
Wang et al. Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma
JP6674889B2 (ja) 前立腺がんに対するバイオマーカー検出における使用のための方法とアレイ
Kohsaka et al. Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling
Hakim et al. Prognostic impact of the loss of E-cadherin and de novo expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma
EP2742358A1 (en) Methods for diagnosing cancer
KR20130046457A (ko) 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트
Cheung et al. Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping
CN105158468B (zh) Ck19联合ov6在制备肝癌分子分型试剂盒及肝癌个体化治疗中的应用
CN116559462A (zh) 用于肿瘤患者预后的生物标志物组及其用途
Xu et al. Decreasing cytokeratin 17 expression in head and neck cancer predicts nodal metastasis and poor prognosis: the first evidence
ES2436667B1 (es) Suero biomarcador para diagnosticar el cáncer colorrectal
US20230416836A1 (en) Method for predicting responsiveness to plk1 inhibition
ES2314272T3 (es) Metodos para el diagnostico y el tratamiento del cancer.
Amer et al. DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer
Özdemir et al. Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer